建發股份(600153.SH):控股子公司已售宏發股份1488萬股股票
格隆匯9月8日丨建發股份(600153.SH)公佈,2021年5月18日至9月7日,公司控股子公司聯發集團有限公司(“聯發集團”)通過集中競價交易方式累計出售宏發股份(600885.SH)1488萬股股票,佔其當前總股本的1.9980%,累計成交金額866,748,396 元。
此次交易完成後,子公司聯發集團繼續持有宏發股份4996.9014萬股,佔其當前總股本的6.71%。
上述交易預計將增加建發股份2021年度歸屬於母公司股東淨利潤約4.68億元(税後、未經審計),約佔公司最近一個會計年度經審計歸屬於母公司股東淨利潤的10.39%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.